Overview

ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
- To compare the Kinetics of inhibition of platelet aggregation (aggregometry) and platelet activation (flow cytometry) with different loading doses of clopidogrel - To evaluate the effect on various parameters of inflammation and necrosis and the safety of these loading doses
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Collaborator:
Bristol-Myers Squibb
Treatments:
Clopidogrel
Ticlopidine